OppenheimerFunds Inc. purchased a new position in Senseonics Holdings Inc (NYSEAMERICAN:SENS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,928,366 shares of the company’s stock, valued at approximately $7,926,000. OppenheimerFunds Inc. owned 1.40% of Senseonics at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in SENS. Gilder Gagnon Howe & Co. LLC purchased a new position in Senseonics during the second quarter valued at $74,936,000. BlackRock Inc. lifted its position in Senseonics by 1,958.6% during the second quarter. BlackRock Inc. now owns 3,811,007 shares of the company’s stock valued at $15,664,000 after purchasing an additional 3,625,877 shares during the last quarter. Broadview Advisors LLC bought a new position in Senseonics during the second quarter valued at $2,774,000. Renaissance Technologies LLC bought a new position in Senseonics during the second quarter valued at $2,285,000. Finally, Millennium Management LLC lifted its position in Senseonics by 43.5% during the first quarter. Millennium Management LLC now owns 1,387,566 shares of the company’s stock valued at $4,163,000 after purchasing an additional 420,358 shares during the last quarter. 30.66% of the stock is owned by hedge funds and other institutional investors.
NYSEAMERICAN:SENS traded up $0.04 during trading hours on Friday, hitting $3.48. 1,697,504 shares of the company were exchanged, compared to its average volume of 1,501,579. Senseonics Holdings Inc has a 52-week low of $2.36 and a 52-week high of $5.29. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.93 and a quick ratio of 2.81.
Several equities research analysts have recently issued reports on the stock. BTIG Research restated a “buy” rating and issued a $6.00 target price on shares of Senseonics in a report on Thursday, August 9th. Dougherty & Co assumed coverage on shares of Senseonics in a report on Friday, August 24th. They issued a “buy” rating and a $6.00 target price for the company. Finally, Raymond James raised their target price on shares of Senseonics from $4.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, June 22nd. Six research analysts have rated the stock with a buy rating, Senseonics currently has an average rating of “Buy” and a consensus price target of $6.00.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: Insider Trading
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.